During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

and symptoms that indicate a more active disease pattern guide treatment initiation for CLL. The International Workshop on CLL has published guidelines. At least one of the following must be ...

Data are now accumulating on the feasibility of various treatment options even in unfit patients and there is an increased awareness that the chronological age by itself sometimes does not reflect ...

If your CLL is in the early stages, you may not need treatment right away. If you do, your treatment will depend on your cancer stage, symptoms, total health, and preferences. Treatment options ...

But when CLL crowds out the healthy cells in your bone marrow and you get symptoms, you may need treatment. That’s what happened to Larry Saltzman, MD, a retired family doctor in Sacramento ...

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...

These findings underscore the importance of aligning treatment strategies with evolving guidelines to improve survival in CLL/SLL. This second study assessed cost offsets associated with covalent ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

that have achieved promising results in Phase I/II studies when available should modify the paradigm of the treatment of elderly patients with CLL. Here, the authors review background data on ...